Definiens Appoints Chief Marketing Officer, Merrilyn Datta, Ph.D.
News Apr 09, 2013
“I am very excited to have Merrilyn join our leadership team. Merrilyn’s expertise will be key to leverage our leadership position in image and data analysis in Life Sciences into Tissue Diagnostics and Clinical Digital Pathology,“ said Definiens CEO Thomas Heydler. “Merrilyn’s great track record in understanding the marketplace and building businesses will be invaluable for driving Definiens’ Marketing and Commercialization activities.”
Prior to joining Definiens, Dr. Datta served as a senior marketing leader for Life Technologies, a global biotechnology company with customers in the fields of scientific research, genetic analysis and applied sciences, where she specialized in technology commercialization and strategy. Her professional background also includes positions as Chief Content Officer, Services Leader and Gene Regulation BU leader.
“Definiens will take tissue analysis into the 21st century by making the information on histological slides accessible to bioinformatics analysis,” said Dr. Datta. “I’m excited to be a part of the team which will not only provide valuable image understanding to accelerate drug discovery, but which also has a roadmap to fundamentally change clinical practice, advance personalized medicine and improve patient outcomes.”
Dr. Datta is based in southern California and will lead Definiens’ marketing activities from the company’s Carlsbad office.
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE
So Hot it Hurts: Ion channel trio underlying painful heat sensation foundNews
Researchers show that acute noxious heat sensing in mice depends on a triad of transient receptor potential (TRP) ion channels: TRPM3, TRPV1, and TRPA1.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE